Ken Griffin Catalyst Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $550 Billion
- Q2 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 259,992 shares of CPRX stock, worth $5.29 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
259,992
Previous 21,200
1126.38%
Holding current value
$5.29 Million
Previous $514,000
997.47%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding CPRX
# of Institutions
385Shares Held
103MCall Options Held
0Put Options Held
277K-
Black Rock Inc. New York, NY18.7MShares$380 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$178 Million0.0% of portfolio
-
State Street Corp Boston, MA5.48MShares$111 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.25MShares$66.1 Million0.1% of portfolio
-
Morgan Stanley New York, NY3.18MShares$64.8 Million0.0% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.09B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...